All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Human leukocyte antigens A2 (HLA-A2), also known as HLA-A*02, is a human leukocyte antigen serotype within the HLA-A serotype group. The serotype is determined by the antibody recognition of the α2 domain of the HLA-A α-chain. For A*02, the α chain is encoded by the HLA-A*02 gene and the β chain is encoded by the B2M locus. In human melanoma, the expression of HLA-A2 antigen in human melanoma expression is related to tumor cell recognition by autologous T Iymphocytes. Furthermore, HLA-A2 appears to be somewhat less effective than other HLA-As at protecting against HIV infections. HLA-A2 is linked with decreased risk of developing Epstein-Barr virus (EBV)-positive Hodgkin lymphoma(HL).
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-MZ109 | Anti-HLA-A2 (BB7.2) h(CD3ζ) CAR, pCDCAR1 | Human | BB7.2 | Mouse | scFv-CD3ζ | Lentiviral | T cell | ||
CAR-MZ110 | Anti-HLA-A2 (BB7.2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | BB7.2 | Mouse | scFv-CD28-CD3ζ | Lentiviral | T cell | ||
CAR-MZ111 | Anti-HLA-A2 (BB7.2) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | BB7.2 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | ||
CAR-M0176-YC | Anti-HLA-A2 (BB7.2) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | Human | BB7.2 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-M0587-YC | Anti-HLA-A2 (BB7.2) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | Human | BB7.2 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0622-ZP3303 | Anti-HLA-A2 h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
XS-0622-ZP3475 | Anti-HLA-A2 h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
XS-0822-YF1432 | Anti-Human HLA-A2 (XW-512) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-512 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF1433 | Anti-Human HLA-A2 (XW-513) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-513 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2352 | Anti-Human HLA-A2 (XW-512) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-512 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2353 | Anti-Human HLA-A2 (XW-513) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-513 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0922-ZP971 | Anti-HLA-A2 (SN607D8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | SN607D8 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0922-ZP1118 | Anti-HLA-A2 (GCT615) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | GCT615 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0922-ZP1281 | Anti-HLA-A2 (SN607D8) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | SN607D8 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-1122-YF1432 | Anti-HLA-A2 TCR-ABR (scFv-TCRα, XW-512) CAR Plasmid, pCDCAR1 | Human | XW-512 | Mouse | scFv-TCRα | Lentiviral vector | T Cell | ||
XS-1122-YF1433 | Anti-HLA-A2 TCR-ABR (scFv-TCRα, XW-513) CAR Plasmid, pCDCAR1 | Human | XW-513 | Mouse | scFv-TCRα | Lentiviral vector | T Cell | ||
XS-1122-YF2352 | Anti-HLA-A2 TCR-ABR (scFv-TCRβ, XW-512) CAR Plasmid, pCDCAR1 | Human | XW-512 | Mouse | scFv-TCRβ | Lentiviral vector | T Cell | ||
XS-1122-YF2353 | Anti-HLA-A2 TCR-ABR (scFv-TCRβ, XW-513) CAR Plasmid, pCDCAR1 | Human | XW-513 | Mouse | scFv-TCRβ | Lentiviral vector | T Cell | ||
XS-0123-ZP624 | Anti-HLA-A2 (SN607D8) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | SN607D8 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
XS-0923-LX48 | Anti-hHLA-A2 (CD28-41BB-CD3ζ) CAR-duplex CTLA4 pCDCAR1 Vector | Human | X9X-17 | scFv-CD28-41BB-CD3ζ-duplex CTLA4 | Lentiviral vector | T cell | CAR-T |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION